Dosimetric calculations (MIRD) for 131I
| . | Intratumoral injections . | Intravenous injections . | ||
|---|---|---|---|---|
| PBS* . | VSV (Δ51)-NIS† . | PBS* . | VSV (Δ51)-NIS† . | |
| Tumor volume, mm3 | 180 | 170 | 190 | 120 |
| Injected activity, MBq 123I | 10.5 | 10.4 | 10.3 | 11.0 |
| Tumor activity, MBq 123I | 0.1 | 0.6 | 0.1 | 0.6 |
| Tumor dose, Gy 131I | 4.2 | 18.4 | 4.1 | 11.6 |
| . | Intratumoral injections . | Intravenous injections . | ||
|---|---|---|---|---|
| PBS* . | VSV (Δ51)-NIS† . | PBS* . | VSV (Δ51)-NIS† . | |
| Tumor volume, mm3 | 180 | 170 | 190 | 120 |
| Injected activity, MBq 123I | 10.5 | 10.4 | 10.3 | 11.0 |
| Tumor activity, MBq 123I | 0.1 | 0.6 | 0.1 | 0.6 |
| Tumor dose, Gy 131I | 4.2 | 18.4 | 4.1 | 11.6 |
Dosimetric calculations were based on imaging studies (with 123I) performed on day 1 after virus administration in mice bearing subcutaneous 5TGM1 myeloma tumors. Mice were given PBS or VSV (Δ51)-NIS (5 × 107 TCID50/dose, 2 doses given 24 hours apart) by intratumoral or intravenous routes.
MIRD indicates medical internal radiation dosimetry.
N=10.
N=20.